<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9688">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692518</url>
  </required_header>
  <id_info>
    <org_study_id>GTM-005</org_study_id>
    <nct_id>NCT05692518</nct_id>
  </id_info>
  <brief_title>MagDI Diversion Feasibility Study</brief_title>
  <official_title>Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System to Achieve Duodeno-Ileostomy Diversion in Adults With Obesity and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GT Metabolic Solutions, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GT Metabolic Solutions, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to evaluate the feasibility of the GT&#xD;
      Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI&#xD;
      Bio-fragmentable) for creation of a side-by-side anastomosis duodeno-ileostomy in obese&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this clinical research study is to evaluate the feasibility of the GT&#xD;
      Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI&#xD;
      Bio-fragmentable) for creation of a side-to-side anastomosis duodeno-ileostomy in obese&#xD;
      adults. This partial diversion of intestinal contents from duodenum to the ileum is intended&#xD;
      to facilitate weight management/loss in obese adults with type 2 diabetes mellitus (T2DM) and&#xD;
      improve metabolic outcomes in obese adults with type 2 diabetes mellitus (T2DM). Side-by-side&#xD;
      anastomoses are currently created by sutures, staples, and anastomotic compression devices. A&#xD;
      predicate procedure is the single-anastomosis duodeno-ileostomy (SADI) procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2022</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-center, open-label, single-arm, feasibility device study.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Creation of a patent anastomosis</measure>
    <time_frame>30 Days</time_frame>
    <description>Confirmed radiologically or fluoroscopically</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>MAGNET System, DI Bio-fragmentable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MAGNET System, DI Bio-fragmentable</intervention_name>
    <description>Anastomoses achieved by magnetic compression.</description>
    <arm_group_label>MAGNET System, DI Bio-fragmentable</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-65 years of age, inclusive, at the time of informed consent&#xD;
&#xD;
          2. BMI 30-35 kg/m2&#xD;
&#xD;
          3. Type 2 diabetes mellitus (T2DM), defined as HbA1c &gt; 6.5%, without previous sleeve&#xD;
             gastrectomy, and without plan to perform a concurrent sleeve gastrectomy.&#xD;
&#xD;
          4. Agrees to refrain from any type of additional bariatric or reconstructive surgery that&#xD;
             would affect body weight for the duration of the study&#xD;
&#xD;
          5. If a child-bearing female, subject must commit to not becoming pregnant and agree to&#xD;
             use contraception for the duration of the study&#xD;
&#xD;
          6. Willing and able to comply with protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes&#xD;
&#xD;
          2. Use of injectable insulin&#xD;
&#xD;
          3. Uncontrolled T2DM&#xD;
&#xD;
          4. Previous sleeve gastrectomy procedure or plan to perform a sleeve gastrectomy with the&#xD;
             duodeno-ileal anastomosis procedure&#xD;
&#xD;
          5. Uncontrolled hypertension, dyslipidemia or sleep apnea&#xD;
&#xD;
          6. Prior intestinal, colonic or duodenal surgery, other than bariatric&#xD;
&#xD;
          7. Prior surgery, trauma, prostheses, disease or genetic expression which prevent or&#xD;
             contra-indicate the procedure, including scarring and abnormal anatomy.&#xD;
&#xD;
          8. Refractory gastro-esophageal reflux disease (GERD)&#xD;
&#xD;
          9. Barrett's disease&#xD;
&#xD;
         10. Helicobacter pylori positive and/or active ulcer disease&#xD;
&#xD;
         11. Large hiatal hernia&#xD;
&#xD;
         12. Inflammatory bowel or colonic diverticulitis disease&#xD;
&#xD;
         13. Any anomaly precluding orogastric access by gastroscope and catheters, and&#xD;
             manipulation techniques.&#xD;
&#xD;
         14. Implantable pacemaker or defibrillator&#xD;
&#xD;
         15. Psychiatric disorder, except well-controlled depression with medication for &gt; 6 mo&#xD;
&#xD;
         16. History of substance abuse&#xD;
&#xD;
         17. Woman who is either pregnant or breast feeding&#xD;
&#xD;
         18. Woman of childbearing potential who does not agree to use an effective method of&#xD;
             contraception.&#xD;
&#xD;
         19. Any comorbidity or current status of subject's physiological fitness that in the&#xD;
             surgeon's or anesthesiologist's opinion represents safety concerns that make the&#xD;
             subject medically unfit for the procedure.&#xD;
&#xD;
         20. Any anomaly preventing/contraindicating laparoscopic access and general laparoscopic&#xD;
             procedures&#xD;
&#xD;
         21. Had surgical or interventional procedure within 30 days prior to procedure&#xD;
&#xD;
         22. Any scheduled surgical or interventional procedure planned within 30 days&#xD;
             post-procedure&#xD;
&#xD;
         23. Any stroke/transient ischemic attack (TIA) within 6 months prior to consent&#xD;
&#xD;
         24. Requires chronic anticoagulation therapy (except aspirin)&#xD;
&#xD;
         25. Active infections requiring antibiotic therapy, unless resolved before undergoing the&#xD;
             study procedure&#xD;
&#xD;
         26. Unable to comply with the follow-up schedule and assessments&#xD;
&#xD;
         27. Recent tobacco or nicotine product cessation within &lt; 3 months prior to informed&#xD;
             consent&#xD;
&#xD;
         28. Known allergies to the device components or contrast media&#xD;
&#xD;
         29. Limited life expectancy due to terminal disease&#xD;
&#xD;
         30. Currently participating in another clinical research study with an investigational&#xD;
             drug or medical device&#xD;
&#xD;
         31. A positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19)&#xD;
             test prior to the study procedure in accordance with local COVID-19 protocol&#xD;
&#xD;
         32. Any condition that, in the investigator's opinion, may preclude completion of&#xD;
             follow-up assessments through Day 360 (e.g., a medical condition that may increase the&#xD;
             risk associated with study participation or may interfere with interpretation of study&#xD;
             results, inability to adhere to the visit schedule, or poor compliance with treatment&#xD;
             regimen)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Griffin Vincent, PhD</last_name>
    <phone>612-222-4200</phone>
    <email>lgv@gtmetabolic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Schwartz, MS</last_name>
    <email>dan@gtmetabolic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Innova Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>N.6</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Abuladze, MD, PhD</last_name>
      <phone>995322232232</phone>
      <email>davidsur@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Magda Abuladze</last_name>
      <phone>995322232232</phone>
      <email>abuladze30@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>May 1, 2023</last_update_submitted>
  <last_update_submitted_qc>May 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

